Blog Archives

Pembrolizumab (Keytruda): Clinical trials on hold

September 2, 2017 – The American Food & Drug Administration (FDA) has announced that two clinical trials with Pembrolizumab (Keytruda) in patients with multiple myeloma have been put on hold. The FDA informs the public, health care professionals, and oncology clinical investigators about the risks associated with the use of Pembrolizumab (Keytruda) in combination with dexamethasone and an immunomodulatory agent (Lenalidomide (Revlimid) or Pomalidomide (Pomalyst)) for the treatment of patients with multiple myeloma.

Read more ›

Tags: , , , , , , , , , , ,

Orlistat: Assessment of Adverse Events in Protocols, Clinical Study Reports, and Published Papers

August 30, 2016 – The present article which just appeared in August 2016 issue of  PLOS Medicine illustrates how the inaccurate and biased to say the least the assessment and the reporting of adverse drug reactions by pharmaceutical companies throughout study protocols, investigators brochures,

Read more ›

Tags: , , , , , ,

Immunemodulation: Cancer drug trial halted after three test subjects die

July 12, 2016 – The American Food & Drug Administration (FDA) has notified Juno Therapeutics Inc. that a clinical hold has been placed on the Phase II clinical trial of JCAR015 in adult patients with relapsed or refractory B cell acute lymphoblastic leukemia (r/r ALL), known as the “ROCKET” trial.

Read more ›

Tags: , , , , , , ,

The betrayed educated patient: A significant percentage of completed clinical trials on drugs are never published

May 01, 2016 – The present post addresses a very disturbing issue in connection with clinical trials and the disclosure of the results in public. The cited study throws a dubios light on the readiness of sponsors to inform patients, i.e. their future end user clients, on the outcome of clinical trials and to openly divulge pros and cons of their products.

Read more ›

Tags: , , , , ,

Under scrutiny: The EMA reviews cancer medicine Idelalisib (Zydelig) after the occurrence of serious adverse effects, some of them fatal, in three clinical trials

 March 20, 2016 – The European Medicines Agency (EMA) has, at the request of the European Commission, has started a review of the cancer medicine Idelalisib (Zydelig), which is authorised in the European Union to treat two types of rare blood cancers called chronic lymphocytic leukaemia (CLL) and follicular lymphoma (FL) (one of a group of cancers called Non-Hodgkin lymphoma).

Read more ›

Tags: , , , , , , , ,

New Treatment Modality: Nivolumab (Opdivo) has been approved for the treatment of patients with previously treated metastatic squamous non-small cell lung cancer (NSCLC)

June 17, 2015 – Bristol Myers Squipp recently announced that the U.S. Food and Drug Administration (FDA) has approved Nivolumab (Opdivo) injection, for intravenous use, for the treatment of patients with metastatic squamous non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy. 

Read more ›

Tags: , , , , , ,

thasso: conditions

thasso: newest tweets

thasso: recent comments

View my Flipboard Magazine.

thasso: categories

thasso: archives

thasso: simple chat

You must be a registered user to participate in this chat.

  • Genomic adaptations to a rice-based diet mitigate the risk of obesity and diabetes September 21, 2020
    The traditional rice-based diet of some east-Asian population has brought a number of genomic adaptations that may contribute to mitigating the spread of diabetes and obesity. An international study led by the University of Bologna and published in the journal Evolutionary Applications has recently suggested this interesting hypothesis. Researchers analyzed and compared the genomes of […]
  • Researchers identify genetic factors associated with hand-foot syndrome in chemotherapy with capecitabine September 21, 2020
    Capecitabine is a chemotherapy drug used for breast and colorectal cancer. It can extend survival rate by nearly 10%. However, recent studies revealed that almost 50% of patients develop palmar-plantar erythrodysesthesia, a skin reaction also called hand-foot syndrome with mild to serious symptoms. Up to 17% of these patients can have a burning pain in […]
  • Gene therapy corrects the cardiac effects of Friedreich's ataxia September 18, 2020
    Gene therapy was successfully used to overcome the cardiac effects of Freidreich's ataxia (FA) in a mouse model of the disease, as reported in the peer-reviewed journal Human Gene Therapy.
  • Algorithms uncover cancers' hidden genetic losses and gains September 17, 2020
    Understanding the specific mutations that contribute to different forms of cancer is critical to improving diagnosis and treatment. But limitations in DNA sequencing technology make it difficult to detect some major mutations often linked to cancer, such as the loss or duplication of parts of chromosomes.
  • Researcher finds keys to control the 'driver of cancer's aggressiveness' September 17, 2020
    'Do not erase.' 'Recycle me.' 'Free to a good home.' Humans post these signs to indicate whether something has value or not, whether it should be disposed of or not. Inside our cells, a sophisticated recycling system uses its own enzymatic signs to flag certain cells for destruction—and a different set of enzymes can remove […]
  • Awareness of COVID-19 in severe dementia patients September 21, 2020
    Tokyo, September 21, 2020- The ongoing coronavirus disease 2019 (COVID-19) pandemic has substantially affected patients with dementia and their caregivers.
  • Cleveland Clinic study finds no link between influenza vaccine and COVID-19 risk September 21, 2020
    Using patient data from Cleveland Clinic's COVID-19 registry, Dr. Joe Zein found that receiving the flu vaccine does not increase risk for COVID-19 or worsen associated disease outcomes, suggesting it is safe and advisable to receive the influenza vaccine this flu season.
  • Bio-based inhibition of gas hydrate formation September 21, 2020
    Copper stearate was used as the basis for this catalyst test and showed efficiency for in-situ oil combustion.
  • Biodiversity hypothesis called into question September 21, 2020
    How can we explain the fact that no single species predominates? A generally accepted hypothesis is that a trade-off exists between organisms able to acquire and consume more food than other when resources are scarce, and organisms which rapidly consume large quantities of food when they are in abundance. However, when scientists from the University […]
  • A faster and more reliable method to categorize olive oil is validated September 21, 2020
    Classifying olive oils into the categories of extra virgin (EVOO), virgin (VOO) and lampante (LOO) is still quite a challenge to deal with since the official method includes physical-chemical and sensory analyses by means of a panel of tasters. These tasters need to be specialized, and on many occasions are not available, in addition to […]
Top